Cantor Fitzgerald Maintains Overweight on Catalyst Pharmaceuticals, Raises Price Target to $34
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan has maintained an Overweight rating on Catalyst Pharmaceuticals (NASDAQ:CPRX) and increased the price target from $27 to $34.
March 01, 2024 | 2:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Charles Duncan reaffirmed an Overweight rating on Catalyst Pharmaceuticals and raised the price target from $27 to $34.
The increase in price target by a reputable analyst suggests a positive outlook on the company's future performance, likely leading to increased investor confidence and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100